Therefore, to avoid cardiac arrhythmia via down-regulation of the fraction of CD4+CD28null cells, a safe and feasible pre-optative stain-therapy could represent a potential therapeutic agent. The gene discussed is CD4; the disease is cardiac rhythm disease.